United States · Bill · HR
H.R. 3209 (112th)
Premarket Predictability Act of 2011
Introduced
14 October 2011
Last action
18 October 2011 · Referred
Status
Referred to the Subcommittee on Health.
Sponsors
Rep. Shimkus, John [R-IL-15], Rep. Gingrey, Phil [R-GA-11], Rep. Guthrie, Brett [R-KY-2], Rep. Altmire, Jason [D-PA-4], Rep. Lance, Leonard [R-NJ-7], Sen. Blackburn, Marsha [R-TN], Rep. Rogers, Mike J. [R-MI-8], Rep. Bilbray, Brian P. [R-CA-50], Rep. Burgess, Michael C. [R-TX-26], Rep. Barton, Joe [R-TX-6], Rep. Paulsen, Erik [R-MN-3], Sen. Cassidy, Bill [R-LA], Rep. Latta, Robert E. [R-OH-5], Rep. Culberson, John Abney [R-TX-7], Rep. Walden, Greg [R-OR-2], Rep. Benishek, Dan [R-MI-1], Rep. Akin, W. Todd [R-MO-2], Rep. Mulvaney, Mick [R-SC-5], Rep. McMorris Rodgers, Cathy [R-WA-5], Rep. Rokita, Todd [R-IN-4], Rep. Matheson, Jim [D-UT-2]
Subjects
Healthcare
Source updated
14 August 2025
Summary
Premarket Predictability Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services (HHS) to assign a tracking number to a medical device upon submission of: (1) an application for an exemption of a device for investigational use, (2) a request to classify a device, or (3) a premarket report or notification related to a device. Requires the Secretary to use the tracking number to record interactions between the Secretary and applicant with respect to the device. Directs the Secretary to: (1) assign a reviewer with prior review experience with the type of of device or technology involved or other relevant expertise to review an application for an exemption of a device for investigational use, and (2) evaluate whether the investigational study can be conducted ethically with reasonable risk in determining whether to grant an exemption for investigational use. Prohibits the Secretary from disapproving an application because the investigation does not or may not meet any requirement relating to the approval or clearance of a device because the Secretary believes that a different clinical testing design or plan could produce data more relevant to an approval or clearance decision. Revises the procedures relating to submission of an application to investigate a class II or a class III device, which may include a plan for determining whether the device is substantially equivalent to or is at least as safe and effective as a legally marketed device that is not subject to premarket approval requirements. Sets forth requirements for the Secretary to meet in determining the least burdensome appropriate means of evaluating medical device effectiveness that would have a reasonable likelihood of resulting in approval. Requires the Secretary to document the scientific and regulatory rationale for any significant decision of the Center for Devices and Radiological Health regarding device review, approval, or exemption. Sets forth appeal procedures. Requires the Secretary to regularly publish detailed decision summaries for each clearance of a device not requiring premarket approval.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
14 October 2011
Introduced
Referred to the House Committee on Energy and Commerce.
Source: IntroReferral
14 October 2011
Introduced
Introduced in House
Source: IntroReferral
14 October 2011
Introduced
Introduced in House
Source: IntroReferral
18 October 2011
Referred
Referred to the Subcommittee on Health.
Source: Committee
Votes
No vote records are attached yet.
Versions
- Introduced in House · 14 October 2011 · Download file
Documents
3 official files
Introduced in House (text)
This file cannot be previewed here. Use View or Download.
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House (text)
Introduced in House · EN · 14 October 2011
Introduced in House (PDF)
Introduced in House · EN · 14 October 2011
ViewDownloadOpen at official source
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Introduced in House
summary · EN · 14 October 2011
Leesvertaling
Vertaal dit document naar jouw taal. PoliticalRepo bewaart geen aparte kopie per EU-taal.
Documentvertaling op verzoek met downloadbare PDF (logo + link naar de officiële bron). Het bronbestand blijft leidend.
Sponsors
- Rep. Shimkus, John [R-IL-15] · R · Sponsor
- Rep. Gingrey, Phil [R-GA-11] · R · Sponsor
- Rep. Guthrie, Brett [R-KY-2] · R · Sponsor
- Rep. Altmire, Jason [D-PA-4] · D · Sponsor
- Rep. Lance, Leonard [R-NJ-7] · R · Sponsor
- Sen. Blackburn, Marsha [R-TN] · R · Sponsor
- Rep. Rogers, Mike J. [R-MI-8] · R · Sponsor
- Rep. Bilbray, Brian P. [R-CA-50] · R · Sponsor
- Rep. Burgess, Michael C. [R-TX-26] · R · Sponsor
- Rep. Barton, Joe [R-TX-6] · R · Sponsor
- Rep. Paulsen, Erik [R-MN-3] · R · Sponsor
- Sen. Cassidy, Bill [R-LA] · R · Sponsor
- Rep. Latta, Robert E. [R-OH-5] · R · Sponsor
- Rep. Culberson, John Abney [R-TX-7] · R · Cosponsor
- Rep. Walden, Greg [R-OR-2] · R · Cosponsor
- Rep. Benishek, Dan [R-MI-1] · R · Cosponsor
- Rep. Akin, W. Todd [R-MO-2] · R · Cosponsor
- Rep. Mulvaney, Mick [R-SC-5] · R · Cosponsor
- Rep. McMorris Rodgers, Cathy [R-WA-5] · R · Cosponsor
- Rep. Rokita, Todd [R-IN-4] · R · Cosponsor
- Rep. Matheson, Jim [D-UT-2] · D · Cosponsor
- · hsif00 · Standing
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/112th-congress/house-bill/3209
- Open data entity: https://api.congress.gov/v3/bill/112/hr/3209
- us · 112-hr-3209 · source updated 14 August 2025